Special Issue "Radioisotope Production and Applications"
A special issue of Applied Sciences (ISSN 2076-3417).
Deadline for manuscript submissions: 31 July 2013
Dr. Paul Schaffer
Head, Nuclear Medicine, TRIUMF, 4004 Wesbrook Mall, Vancouver, BC, Canada V6T 2A3
Phone: +1 604 222 7696
Fax: +1 604 222 1074
Interests: radiochemistry; radiopharmaceutical development; molecular imaging; positron emission tomography, radioisotope production and applications
Molecular imaging has enabled health professionals and basic researchers to probe the function of living systems at the molecular level, enabling non-invasive studies into functional changes that take place during the onset and progression of disease, well before anatomical changes occur. Understanding the molecular progression of disease is changing the way it is diagnosed, staged and treated and will ultimately enable a paradigm of personalized healthcare.
Between 20 and 40 million single photon- and positron emission tomography (SPECT and PET) scans are performed each year around the world in patients suffering from heart ailments, cancer and neurological diseases like Parkinson’s and Alzheimer’s. With new biological questions about these diseases (and others) continuously emerging, novel ways of producing medical isotopes, converting them into radiopharmaceuticals and demonstrating in vivo efficacy are of paramount importance. Such an effort requires amalgamation of basic and applied research across the disciplines of physics, chemistry and biology—all of which are geared toward the development of better imaging protocols or contrast-enhancing biological probes.
The widespread acceptance of new and promising radioisotopes and radiopharmaceuticals is typically challenged by their availability and accessibility. Despite the advances in availability of medical cyclotrons in the hospital setting, new isotope production, isolation and application remains a difficult task for most institutions. Couple this with the anticipated shutdown of the world’s major 99mTc production reactor and accelerator-based production facilities will face an increasing responsibility to meet isotope demands of the healthcare community.
The need to install novel infrastructure and/or purchase isotope generators necessitates a substantial technical and financial commitment that may be difficult to justify, especially if preliminary biological studies are warranted to establish proof of feasibility for the isotopes in question. These obstacles likely inhibit the development of novel tracers that may possess a better match between the physical half-life of a promising new radioisotope and the pharmacokinetic profile of the vector to which it is attached.
This special issue of Applied Sciences, titled “Radioisotope Production and Application” aims to cover recent advances in the development of new and promising production methods for metallic and non-metallic medical isotopes, as well as new radiochemical techniques for radiopharmaceutical production and their use in novel applications. Reviews are also welcome.
Dr. Paul Schaffer
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Applied Sciences is an international peer-reviewed Open Access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. For the first couple of issues the Article Processing Charge (APC) will be waived for well-prepared manuscripts. Article Processing Charge (APC) will be waived for well-prepared manuscripts submitted before the end of 2012, Article Processing Charge will be 300 CHF from 2013. English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.
- cyclotron target design, operation
- isotope production, isolation
- medical radioisotopes
- radiopharmaceutical chemistry
- positron emission tomography (PET)
- single photon emission computed tomography (SPECT)
- molecular imaging
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Type of Paper: Article
Title: Routine Production of 89Zr Using an Automated Module
Authors: A. Lake Wooten 1,2, Gordon D. Schweitzer 1, Luke A. Lawrence 1, Evelyn Madrid 1, Efrem Mebrahtu 1 and Suzanne E. Lapi 1,2,*
Affiliation: 1 Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA; E-Mail: firstname.lastname@example.org
2 Department of Biomedical Engineering, Washington University in St. Louis, St. Louis, MO 63130, USA
Abstract: 89Zr has emerged as a useful radioisotope for targeted molecular imaging via positron emission tomography (PET). This isotope is particularly attractive for cancer research because its half-life (t1/2=3.3 d) is well-suited for in vivo targeting of macromolecules and nanoparticles; furthermore, 89Zr emits a low-energy positron (Eβ+,mean=0.40 MeV). Fortunately, a straightforward method has been published for production and chemical separation of 89Zr from a natural Y target. In this work, we have designed, built, and automated a remote module that has been placed in a lead hot cell, where it has separated 89Zr safely and routinely with high radionuclidic purity and satisfactory effective specific activity (ESA).
Last update: 10 April 2013